Loading
A phase 2 trial of SKB571 for injection in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities is a phase 2 interventional study registered as NCT07308106 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 70 participants planned, started 2026-04-03 and due to reach its primary completion in 2027-06-30. Interventions recorded: SKB571 for injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/